T-cell Engager Approved for Aggressive Lung Cancer
The FDA has converted the accelerated approval of tarlatamab-dlle to a full approval for previously treated adults with extensive-stage...
Progress Against Cancer
The FDA has converted the accelerated approval of tarlatamab-dlle to a full approval for previously treated adults with extensive-stage...
The FDA granted accelerated approval to sevabertinib for previously treated adults with HER2‑mutant non‑squamous non‑small cell lung cancer. The...
Daratumumab and hyaluronidase-fihj is now indicated as part of a combination therapy for the potentially fatal condition that can...
FDA expands selumetinib approval to include treatment of adults with inoperable plexiform neurofibromas. The U.S. Food and Drug Administration...
The FDA approved epcoritamab-bysp as a monotherapy or with lenalidomide and rituximab for relapsed or refractory follicular lymphoma. The...
The FDA approved pertuzumab-dpzb for interchangeable use with pertuzumab. The U.S. Food and Drug Administration (FDA) has approved pertuzumab-dpzb...
The FDA has approved the menin inhibitor ziftomenib for adults with relapsed or refractory acute myeloid leukemias harboring susceptible...
The FDA approved daratumumab and hyaluronidase-fihj for adults with smoldering multiple myeloma that has a high risk of progression. ...
The FDA has approved the menin inhibitor revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1...
The FDA approved the BCMA-targeted antibody-drug conjugate belantamab mafodotin-blmf as part of a combination therapy for adults with refractory...